Verge Genomics
Verge Genomics, based in South San Francisco, uses artificial intelligence and human data to accelerate drug discovery and development, focusing on diseases like ALS, Parkinson's, and Frontotemporal Dementia.
Services
Verge Genomics leverages artificial intelligence and human data to accelerate drug discovery and development. Their end-to-end technology-driven platform integrates large human genomics datasets with machine learning to identify potential new drugs. They focus on developing drugs for major medical challenges like amyotrophic lateral sclerosis (ALS), Parkinson's Disease, and Frontotemporal Dementia. Verge Genomics is pioneering AI-powered drug discovery through a human-centric biology and chemistry approach.
Founders
Verge Genomics was born from the convergence of several technological forces, including human genomics, machine learning, biological engineering, and translational medicine. Its founding team aimed to harness these technologies to transform the drug discovery process. Specific details about the individual founders are not provided, but their vision has guided the company to build one of the industry's largest proprietary multi-omics databases directly from human tissue.
Products
Verge Genomics has introduced their first drug, VRG50635, into the clinic. This small molecule inhibitor of PIKfyve is targeted at treating amyotrophic lateral sclerosis (ALS). The company is also involved in developing multiple breakthrough opportunities for diseases like Parkinson's Disease and Frontotemporal Dementia, which currently have no effective treatments. Their aim is to bring these drugs to market faster using their AI-driven drug discovery platform.
Sector
Verge Genomics operates within the healthcare sector, specifically in drug discovery and delivery. The company is headquartered in South San Francisco, CA, and has a team of approximately 50 employees. They focus on using cutting-edge technology, such as artificial intelligence and machine learning, to streamline the drug development process. Their work primarily targets devastating diseases that lack effective treatments, emphasizing a human-centric approach to biology and chemistry.
History
Founded as part of the Y-Combinator S15 batch, Verge Genomics aims to revolutionize drug discovery through technological innovation. The company is headquartered in South San Francisco, CA, and has established itself as a leader in AI-powered drug discovery. Their proprietary patient genomics datasets and multi-omics databases are some of the most comprehensive in the field. Collaborating with industry leaders, Verge Genomics aspires to become a lasting biotechnology company of the digital age.
News
Verge Genomics maintains a news section on their website that features various types of content, including press releases, news coverage, events, and blog posts. This section provides updates on their latest projects, collaborations, and advancements in drug discovery. Users can access all the related press releases and news articles through their website.